Latest Intelligence on Cardiovascular and Diabetes in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

BMS/Sanofi: new Aprovel approval likely in the EU

EU approval for the additional indication should follow within four months, making Aprovel the first AIIRB approved for such an indication and placing it at a significant advantage over the class leaders, Merck's Cozaar and Novartis' Diovan. However, BMS and Sanofi will have to submit more data to the FDA before they can gain the same advantage in the US.

Published By Datamonitor
13 Mar 2002
CommentWire
CommentWire

Boehringer Ingelheim: Pradaxa approval is a mixed blessing

FDA approval in stroke prevention in atrial fibrillation presents Boehringer Ingleheim with a crucial opportunity for Pradaxa before competition heats up to replace warfarin. However, the FDA has sent a strong message that Pradaxa is not the treatment revolution many had expected, as the approved doses are not the two Boehringer would have hoped for.

Published By Datamonitor
20 Oct 2010
CommentWire
CommentWire

Boehringer Ingelheim: stroke drug may harm patients

The aptiganel results are just the latest in a string of disappointing results for neuroprotective agents in acute stroke. This casts serious doubt on this drug class' role in acute stroke, dashing early hopes that neuroprotective agents would fulfill a major unmet need in the anti-thrombosis market.

Published By Datamonitor
05 Dec 2001
Expert View
Expert View

Bristol-Myers damp squib

After a spate of set backs Bristol-Myers Squibb has been forced to make a profit warning. While generic competition has eaten away at sales, the company's pipeline has failed to produce drugs capable of bolstering the waning revenues. So, with no signs of a reprieve, will Bristol-Myers be able to fight off unwelcome suitors or is a take-over in the offing?

Published By Datamonitor
26 Apr 2002
Expert View
Expert View

Bristol-Myers-Squibb: poor targeting triggers Vanlev delays

Last month an FDA advisory panel turned down Bristol-Myers Squibb's application for hypertension drug Vanlev. The drug's launch will now be delayed while the company prepares new evidence. However, with unmet need remaining high in resistant and niche indications, this delay could have been avoided. So will Vanlev recover to become the blockbuster Bristol-Myers hoped it would be?

Published By Datamonitor
09 Aug 2002
CommentWire
CommentWire

British Biotech: moving away from its disastrous past

The news indicates a further step in British Biotech's slow recovery from the poor performance of marimastat and the recent trial results from its Biodiv Ysio stent. However, the company still needs to find a promotion partner for the new thrombolytic if it is to continue to expand its pipeline.

Published By Datamonitor
27 Mar 2002
ResearchWire
ResearchWire

Cardiovascular advertising: dyslipidemia is 97% of spend

Published By Datamonitor
17 May 2001
ResearchWire
ResearchWire

Cardiovascular drugs: hypertension leads, but others catching up

Published By Datamonitor
28 Mar 2001
CommentWire
CommentWire

Cardiovascular risk: polymeal, not polypill

Instead of taking the 'polypill' (a combination of cardiovascular drugs) to reduce the risk of cardiovascular disease, opting for the 'polymeal', a combination of foods with demonstrated positive effects on the heart, may be a tastier alternative. The idea of a polymeal represents a realistic, if fairly light hearted, means of addressing the healthy eating question.

Published By Datamonitor
20 Dec 2004
CommentWire
CommentWire

Carvedilol: COMET leaves questions

The primary results of the COMET trial showed that carvedilol-treated patients had a 17% lower mortality rate than metoprolol-treated patients. However, the trial used immediate release rather than controlled release metropolol, leaving doubts over the validity of the comparison.

Published By Datamonitor
26 Jun 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.